

Corinne
Goldsmith
Dickinson
Center for
Multiple
Sclerosis



Icahn
School of
Medicine at
Mount
Sinai

Friends & Family

Friends and Family of persons with MS are invited to participate in a research study on risk and protective factors for cognitive decline. Participants must be 20 to 50 years old and not have any neurologic disease.

Participants will complete tests of cognitive and physical function and answer questionnaires. Procedures take about 3 ½ hours, and are repeated after three years. There is an optional MRI, which would take an additional hour. Participants are compensated for their time and effort.

Interested persons should contact the research team led by Dr. James F. Sumowski at RESERVE@mssm.edu.



National Institutes of Health
Turning Discovery Into Health

GCO# 16-0746

PI: James F. Sumowski, Ph.D.

IRB approved through 04/05/2018



Memory Clinical Trial

Persons with MS and memory decline are invited to consider a 14-week phase-two clinical trial of atomoxetine (Strattera): a non-stimulant drug FDA approved for children and adults with ADHD.

Eligibility: (a) *diagnosis of MS*, (b) *age 21-60 years*; (c) *memory deficits (assessed by study team)*; (d) *no ADHD, neurologic disease (other than MS), bipolar disorder, current depression, recent suicidal thoughts, liver or heart disease, or narrow angle glaucoma*; (d) *cannot be pregnant or breastfeeding*; (e) *cannot be taking certain medications (e.g., Prozac, Paxil, study physician will review your medications)*.

Procedures: (a) *20-minute eligibility screen*, (b) *1-hour baseline memory assessment*, (c) *randomization to atomoxetine or placebo for six weeks*, (d) *follow-up memory assessment*, (e) *crossover to placebo or atomoxetine for six weeks*, and (e) *final follow-up memory assessment*.

Interested persons should contact the research team led by Dr. James F. Sumowski at RESERVE@mssm.edu.

GCO# 16-1552;

PI: James F. Sumowski, Ph.D.,

Associate Professor of Neurology

Corinne G. Dickinson Center for MS

5 East 98th Street, 1st Floor,

New York, NY 10028

Icahn School of Medicine at Mount Sinai

Protocol: IRB-16-01030

Approved: 06/09/2017

Expires: 01/02/2018